Last reviewed · How we verify
NCT03383835
Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer
NA trial testing Omega-3 Supplementation in Breast Cancer in 11 participants. Status unknown.
8 August 2019
Quick facts
| Lead sponsor | Lauren Nye |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 11 |
| Start date | 5 February 2018 |
| Primary completion | 8 August 2019 |
| Estimated completion | 1 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Omega-3 Supplementation — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Lauren Nye
Who can join
Adults 21 to 40, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot study is an investigation of feasibility of moderate dose omega-3 fatty acid supplementation in pre-menopausal women at high risk for breast cancer who are considering future pregnancy. The goal of this pilot study is to determine feasibility of the study, document compliance with omega-3 fatty acid supplementation in this population and identify novel biomarkers modulated by moderate dose omega-3 fatty acids in this population.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Role of Gut Microbiota in Breast Cancer and Drug Resistance.
Viswanathan S, Parida S, Lingipilli BT, Krishnan R, et al · · 2023 · cited 38× · PMID 36986390 · DOI 10.3390/pathogens12030468 -
Microbiome-targeted nanoplatforms and engineering approaches in breast cancer therapy.
Sabeel Z, Yang Z. · · 2025 · cited 2× · PMID 41168838 · DOI 10.1186/s12943-025-02456-x
Verify or expand the search:
- PubMed search for NCT03383835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Omega-3 Supplementation
Trials testing the same drug.
- NCT07050524 — Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial · Phase 2 · not yet recruiting
- NCT06881966 — The Effect of Omega-3 Fatty Acids in Patients With Rheumatoid Arthritis · NA · not yet recruiting
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03383835 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lauren Nye
- Last refreshed: 23 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03383835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing